SGLT2i

DRUG6 trials

Conditions

Acute Decompensated Heart FailureCardiac Allograft VasculopathyCardiologyCardiovascular DiseasesHeart Failure With Reduced Ejection FractionObesityRejection Heart TransplantTransplant; Failure, Heart

Phase 2

Impact of SGLT2 Inhibitors in Heart Transplant Recipients

Enrolling by invitationNCT06147271

Universidade Federal do CearaCardiac Allograft Vasculopathy, Rejection Heart Transplant, Transplant; Failure, Heart

Start: 2023-11-20End: 2025-08-01Target: 80Updated: 2024-05-07

Phase 4

HF Patients With LVADs Being Treated With SGLT2i

CompletedNCT05278962

University of ChicagoHeart Failure With Reduced Ejection Fraction

Start: 2022-09-08End: 2025-08-31Updated: 2025-09-09

The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

TerminatedNCT05346653

University of ChicagoAcute Decompensated Heart Failure

Start: 2023-05-22End: 2023-05-23Updated: 2024-09-04

Unknown Phase

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

CompletedNCT05073692

Kaiser PermanenteCardiovascular Diseases, Type 2 Diabetes Mellitus

Start: 2021-07-01End: 2025-03-12Updated: 2025-11-21

Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity

CompletedNCT05535322

Ana PalancaObesity, Type 2 Diabetes

Start: 2014-01-01End: 2022-09-01Updated: 2022-09-28

Speckle tracking echocardiographic study of gliflozins effect on rheumatic mitral regurgitation.

Active, not recruitingPACTR202511489850900

Assiut universityCardiology

Start: 2026-04-01Target: 216Updated: 2026-01-27

Related Papers

Rationale and design of Dapagliflozin vErsus SacubiTrIl-valsartaN therapY in Heart Failure with reduced ejection fraction (DESTINY-HF): a pragmatic randomised controlled trial protocol

BMJ Open2024-10-011 citations

Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes